These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 18512184)
21. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. Winstock AR; Kaar S; Borschmann R J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475 [TBL] [Abstract][Full Text] [Related]
22. The hallucinogens and the inhalants. Cohen S Psychiatr Clin North Am; 1984 Dec; 7(4):681-8. PubMed ID: 6097885 [TBL] [Abstract][Full Text] [Related]
23. Pharmacologic Similarities and Differences Among Hallucinogens. Waters K J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556 [TBL] [Abstract][Full Text] [Related]
25. LSD-associated "Alice in Wonderland Syndrome"(AIWS): A Hallucinogen Persisting Perception Disorder (HPPD) Case Report. G Lerner A; Lev-Ran S Isr J Psychiatry Relat Sci; 2015; 52(1):67-8. PubMed ID: 25841113 [TBL] [Abstract][Full Text] [Related]
26. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002 [TBL] [Abstract][Full Text] [Related]
27. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Espiard ML; Lecardeur L; Abadie P; Halbecq I; Dollfus S Eur Psychiatry; 2005 Aug; 20(5-6):458-60. PubMed ID: 15963699 [TBL] [Abstract][Full Text] [Related]
28. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Baggott MJ; Coyle JR; Erowid E; Erowid F; Robertson LC Drug Alcohol Depend; 2011 Mar; 114(1):61-7. PubMed ID: 21035275 [TBL] [Abstract][Full Text] [Related]
30. Hallucinogen Use and Misuse in Older Adults. Redden WM; Paracha SU; Sheheryar Q Clin Geriatr Med; 2022 Feb; 38(1):55-66. PubMed ID: 34794703 [TBL] [Abstract][Full Text] [Related]
31. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation. Lev-Ran S; Feingold D; Rudinski D; Katz S; Arturo LG Am J Addict; 2015 Apr; 24(3):197-199. PubMed ID: 25808913 [TBL] [Abstract][Full Text] [Related]
32. The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F Front Psychiatry; 2017; 8():240. PubMed ID: 29209235 [TBL] [Abstract][Full Text] [Related]
33. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. Sousa TR; Rema J; Machado S; Novais F Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736 [TBL] [Abstract][Full Text] [Related]
34. To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder. Christensen JA; Fipps DC; Bostwick JM Exp Clin Psychopharmacol; 2023 Apr; 31(2):300-304. PubMed ID: 36048112 [TBL] [Abstract][Full Text] [Related]
35. Who takes the trip? Personality and hallucinogen use among college students and adolescents. Parnes JE; Kentopp SD; Conner BT; Rebecca RA Drug Alcohol Depend; 2020 Dec; 217():108263. PubMed ID: 32932162 [TBL] [Abstract][Full Text] [Related]
36. Psilocybin--summary of knowledge and new perspectives. Tylš F; Páleníček T; Horáček J Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771 [TBL] [Abstract][Full Text] [Related]
37. A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Kleinman JE; Gillin JC; Wyatt RJ Schizophr Bull; 1977; 3(4):560-86. PubMed ID: 271353 [No Abstract] [Full Text] [Related]